Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994883871> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2994883871 endingPage "S867" @default.
- W2994883871 startingPage "S867" @default.
- W2994883871 abstract "Hemophilia A patients with inhibitors receiving emicizumab prophylaxis (EP) have the advantage of reducing annual bleeding rate (ABR) compared with on-demand therapy using bypassing agents (OD-BPA) (87.0% reduction, 95% CI: 72.3%-94.3%). Change in the route of administration from intravenous injection of OD-BPA to subcutaneous injection of emicizumab is deemed beneficial as well. The aim of this study is to examine the perceived improvement of quality of life (QOL) of EP compared with OD-BPA in Korean hemophilia patients. A self-administered survey involving 70 hemophilia patients (Either type A or B) at least 20 years of age was conducted at Korea Hemophilia Association Camp on August 10th, 2018. In the questionnaire, two hypothetical treatment scenarios (i.e., EP vs OD-BPA) describing overall symptoms and discomfort of hemophilia A with inhibitors, treatment effectiveness, and route of administration were provided. Then, hemophilia subjects completed their perceived QOL for each scenario using the EuroQol 5-dimensional 5-level instrument (EQ-5D-5L; EQ-5D™ is a trade mark of the EuroQol Research Foundation. (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/faqs/)). EQ-5D-5L responses were converted to utility weights ranging from 0 to 1 using the Korean tariff. The mean age of the respondents was 40 years old (SD: 15.92). Of the respondents, 55 (79%) were patients with type A hemophilia and 11 (16%) had inhibitors. The average utility for EP (0.77±0.16) was significantly higher than that of OD-BPA (0.63±0.20, p<0.05). The improvement of utility for EP compared to OD-BPA was more apparent in patients with inhibitors (0.77 vs. 0.61) than those without inhibitors (0.76 vs. 0.64). The significant improvement of perceived QOL for EP compared to OD-BPA suggests that EP would be a preferred intervention option for hemophilia A patients with inhibitors." @default.
- W2994883871 created "2019-12-26" @default.
- W2994883871 creator A5002967397 @default.
- W2994883871 creator A5032033131 @default.
- W2994883871 creator A5036887248 @default.
- W2994883871 creator A5044965308 @default.
- W2994883871 creator A5049421316 @default.
- W2994883871 creator A5053081150 @default.
- W2994883871 creator A5073124554 @default.
- W2994883871 date "2019-11-01" @default.
- W2994883871 modified "2023-09-26" @default.
- W2994883871 title "PRO141 ESTIMATING UTILITY WEIGHTS IN HEMOPHILIA A PATIENTS WITH INHIBITORS USING THE EQ-5D-5L TOOL: A COMPARISON OF EMICIZUMAB PROPHYLAXIS VERSUS ON-DEMAND TREATMENT WITH BYPASSING AGENTS" @default.
- W2994883871 doi "https://doi.org/10.1016/j.jval.2019.09.2470" @default.
- W2994883871 hasPublicationYear "2019" @default.
- W2994883871 type Work @default.
- W2994883871 sameAs 2994883871 @default.
- W2994883871 citedByCount "0" @default.
- W2994883871 crossrefType "journal-article" @default.
- W2994883871 hasAuthorship W2994883871A5002967397 @default.
- W2994883871 hasAuthorship W2994883871A5032033131 @default.
- W2994883871 hasAuthorship W2994883871A5036887248 @default.
- W2994883871 hasAuthorship W2994883871A5044965308 @default.
- W2994883871 hasAuthorship W2994883871A5049421316 @default.
- W2994883871 hasAuthorship W2994883871A5053081150 @default.
- W2994883871 hasAuthorship W2994883871A5073124554 @default.
- W2994883871 hasBestOaLocation W29948838711 @default.
- W2994883871 hasConcept C126322002 @default.
- W2994883871 hasConcept C159110408 @default.
- W2994883871 hasConcept C1862650 @default.
- W2994883871 hasConcept C187212893 @default.
- W2994883871 hasConcept C2778464720 @default.
- W2994883871 hasConcept C2779134260 @default.
- W2994883871 hasConcept C2779951463 @default.
- W2994883871 hasConcept C3019006561 @default.
- W2994883871 hasConcept C71924100 @default.
- W2994883871 hasConceptScore W2994883871C126322002 @default.
- W2994883871 hasConceptScore W2994883871C159110408 @default.
- W2994883871 hasConceptScore W2994883871C1862650 @default.
- W2994883871 hasConceptScore W2994883871C187212893 @default.
- W2994883871 hasConceptScore W2994883871C2778464720 @default.
- W2994883871 hasConceptScore W2994883871C2779134260 @default.
- W2994883871 hasConceptScore W2994883871C2779951463 @default.
- W2994883871 hasConceptScore W2994883871C3019006561 @default.
- W2994883871 hasConceptScore W2994883871C71924100 @default.
- W2994883871 hasLocation W29948838711 @default.
- W2994883871 hasOpenAccess W2994883871 @default.
- W2994883871 hasPrimaryLocation W29948838711 @default.
- W2994883871 hasRelatedWork W1509473538 @default.
- W2994883871 hasRelatedWork W1935902567 @default.
- W2994883871 hasRelatedWork W2120485647 @default.
- W2994883871 hasRelatedWork W2166715195 @default.
- W2994883871 hasRelatedWork W2352080890 @default.
- W2994883871 hasRelatedWork W2410491650 @default.
- W2994883871 hasRelatedWork W2752094163 @default.
- W2994883871 hasRelatedWork W2802747331 @default.
- W2994883871 hasRelatedWork W2973108776 @default.
- W2994883871 hasRelatedWork W4223487230 @default.
- W2994883871 hasVolume "22" @default.
- W2994883871 isParatext "false" @default.
- W2994883871 isRetracted "false" @default.
- W2994883871 magId "2994883871" @default.
- W2994883871 workType "article" @default.